Summary & Overview
HCPCS J9029: Intravesical Nadofaragene Firadenovec, Per Therapeutic Dose
HCPCS Level II code J9029 denotes intravesical instillation of nadofaragene firadenovec-vncg billed per therapeutic dose. This code captures a targeted, bladder-directed gene therapy administration intended for local treatment, and it matters nationally as a distinct billing element for providers treating bladder conditions with novel biologic agents. Accurate use of J9029 affects clinical documentation, payer coverage determinations, and facility reimbursement workflows for outpatient urology and ambulatory infusion settings.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how the code is defined, typical sites of service, and the clinical context for intravesical administration. The publication also summarizes payer coverage considerations and common billing practices tied to dosing and per-therapeutic-dose reporting.
This piece provides benchmarks and policy-relevant information useful for billing teams, compliance officers, and urology clinicians who need to align documentation and coding with payer rules. It highlights where data is available and notes areas where input does not provide details so that readers can identify gaps requiring payer-specific confirmation.
Billing Code Overview
HCPCS Level II code J9029 represents an intravesical instillation of nadofaragene firadenovec-vncg, billed per therapeutic dose. The service involves administration of a therapeutic agent directly into the bladder (intravesical) for local treatment.
Service type: Intravesical therapeutic instillation
Typical site of service: Outpatient infusion/ambulatory procedure setting or urology clinic
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) who presents to an outpatient urology clinic or ambulatory surgery center for intravesical gene therapy. The patient has previously undergone cystoscopic evaluation confirming residual or recurrent carcinoma in situ or high-grade Ta/T1 disease and has been counseled on intravesical nadofaragene firadenovec-vncg therapy. On the day of service the patient arrives for a scheduled procedure: vital signs and consent are confirmed, a urine specimen is obtained to exclude active infection, and pre-procedure orders (antibiotics per protocol if indicated) are reviewed. Under sterile technique, a catheter is inserted into the bladder, bladder is drained, and the prescribed therapeutic dose of J9029 (nadofaragene firadenovec-vncg) is instilled intravesically. The patient retains the agent for the instructed dwell time (typically about one hour) and is monitored for immediate adverse reactions. Post-procedure documentation includes the lot number, dose, administration route (intravesical), any modifiers applicable to the visit, patient tolerance, and follow-up instructions for surveillance cystoscopy and possible repeat instillation per protocol. Typical sites of service are an outpatient urology clinic, ambulatory surgery center, or hospital outpatient department.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |